Topic Hub
5 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 5 of 5 clinical reviews.
Evidence-based review of flibanserin safety differences in Hispanic and Latino populations, including CYP enzyme pharmacogenomics, metabolic considerations, and clinical trial subgroup data.
Read clinical reviewA clinician-focused review of flibanserin (Addyi) pharmacogenomics, safety signals, and dosing considerations specific to patients of Black or African ancestry, with ethnicity-stratified trial data and guideline citations.
Read clinical reviewFlibanserin (Addyi) may work differently in East Asian women due to CYP2C19/CYP2D6 pharmacogenomic variation. This clinical review covers ethnicity-stratified trial data, pharmacokinetic differences, dosing considerations, and what clinicians need to know before prescribing.
Read clinical reviewA clinical review of flibanserin (Addyi) efficacy differences in Hispanic and Latino women, covering ethnicity-stratified trial subgroups, CYP2C19 pharmacogenomics, and practical dosing considerations.
Read clinical reviewEvidence-based guide to flibanserin (Addyi) dosing considerations for Black and African ancestry patients, including pharmacogenomic factors, CYP2C19 polymorphisms, and clinical trial subgroup data.
Read clinical review